Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Bitcoin Price Faces $84K-$87K Liquidity Zone as Bearish Setup Emerges

Bitcoin Price Faces $84K-$87K Liquidity Zone as Bearish Setup Emerges

CoinpediaCoinpedia2026/10/06 01:36
Story Highlights
  • BTC is sitting inside a heavy $84-$87K liquidity zone.

  • Analysts see $82-$83K as the first downside target if BTC turns lower.

  • A break below $80K-$81K could expose BTC to $76K-$78K liquidity.

The Bitcoin price is sitting in a heavy $84000 – $87000 liquidity zone, and analysts are increasingly describing the setup as bearish. One view says BTC could still squeeze toward $87,000-$88,000 first, clearing upside liquidity before the market turns lower.

That makes the current range a critical battleground. A breakout isn’t guaranteed, and neither is the projected sell-off.

Bitcoin Price Faces Heavy Liquidity Above

Bitcoin Price Faces $84K-$87K Liquidity Zone as Bearish Setup Emerges image 0

It’s a fairly simple thesis: one final push higher, followed by a deeper liquidity sweep. Whether the market actually follows that script is another matter.

Analysts Mark $82K-$83K As First Target

If BTC turns lower, the first downside target sits around $82K-$83K. A break through that area would put the larger $80K-$81K liquidity cluster into focus. That’s where the bearish setup becomes more serious.

The analyst’s theory identifies $80K-$81K as the major liquidity area below current levels. If that cluster fails, the projected move extends toward $76K-$78K, described as the location of the biggest untouched liquidity.

Bitcoin Price Faces $84K-$87K Liquidity Zone as Bearish Setup Emerges image 1

A Deeper Flush Could Follow $80K Breakdown

The bearish argument ultimately depends on those lower levels being taken. A move through $80K-$81K would open the path toward $76K-$78K under the supplied scenario.

For now, however, Bitcoin price remains inside the $84K-$87K liquidity zone, with $87K-$88K representing the potential final upside sweep before the projected decline.

News Image 0News Image 1News Image 2
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released

October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)

路透社•2026/10/06 07:26